International Clinical Trial: Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07532525) titled 'Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma' on April 9.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: University of Michigan Rogel Cancer Center

Condition: Recurrent B Acute Lymphoblastic Leukemia Recurrent B-Cell Non-Hodgkin Lymphoma Refractory B Acute Lymphoblastic Leukemia Refractory B-Cell Non-Hodgkin Lymphoma

Intervention: Procedure: Biospecimen Collection

Recruitment Status: Not recruiting

Phase: Phase...